Cannvas MedTech (CSE:MTEC) (Frankfurt:3CM) (OTC:CANVF), a leading digital cannabis educator and business technology company, is pleased to announce the signing of a definitive contract positioning Cannvas.Me as the exclusive provider of cannabis education and information to members of Medical Marihuana Patient Relief Inc. (“MM Patient Relief”), a private, locally-owned business based in Tecumseh, Ontario focused on creating high-quality, in-demand medical cannabis strains.

“We are thrilled to join MM Patient Relief in their mission to become a leading licenced producer of medical cannabis as we share similar goals of delivering physician-backed alternative therapy solutions to traditional pharmaceuticals using the power of data and analytics to offer a more personalized health care experience,” said Steve Loutskou, Chief Operating Officer, Global Markets, Cannvas MedTech Inc. “Working with Cannvas enables MM Patient Relief members to access evidence-based cannabis education through the Cannvas.Me platform directly through the MM Patient Relief web portal, engaging members in active learning and providing a resource for those curious to learn more about the potential health benefits of cannabis.”


Established in 2014, Medical Marihuana Patient Relief Inc. is currently in the final stages of review and approval under Health Canada’s MMPR/ACMPR (Access to Cannabis for Medical Purposes Regulations). Once approved, it plans to use its proprietary technology to increase the crop yield and quality of cannabis produced in its newly-renovated stand-alone 10,000 sq.ft. building in Tecumseh, Ontario.

“MM Patient Relief understands how vital it is for Canadians to clearly understand their health care options amid an ever-changing medical landscape and learn whether cannabis is a viable alternative treatment that fits within their lifestyle,” said Daniel Davidzon, Director of Strategy and Education, Cannvas MedTech Inc. “By providing its members with physician-backed and educator-approved cannabis education through the Cannvas.Me platform, MM Patient Relief helps empower its clients to make better decisions about their own well-being as they navigate news and articles pertaining to cannabis and its potential health benefits.”

Once fully integrated with the MM Patient Relief portal, members will be able to Cannvas.Me content from anywhere in the world. Cannvas.Me will work closely with MM Patient Relief’s partner network to source information and collaborate on articles to meet the needs of MM Patient Relief clients across Canada.

About Medical Marihuana Patient Relief
Established in 2014, Medical Marihuana Patient Relief Inc. (MMPatient Relief) is a private, locally-owned business based in Tecumseh, Ontario focused on creating high-quality, in-demand medical cannabis strains for pain, arthritis, and cancer. Using advanced cultivation methods that maximize production and have increased the number of yearly crop cycles from four to six, MM Patient Relief is in the final stage of Health Canada MMPR / ACMPR (Access to Cannabis for Medical Purposes Regulation) approval and finalizing construction of its state-of-the-art stand-alone facility. For more information: www.mmpatientrelief.com

About Cannvas MedTech Inc.
Cannvas MedTech is a leading digital cannabis education and business technology company within the health sciences space. We design and build patient-centric platforms that enable our partners to harness the power of data to truly understand their customers.

No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.

Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer’s future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties.  For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.

For further information: Visit cannvas.com

Related Links

https://cannvasmedtech.com

Click here to connect with Cannvas MedTech (CSE:MTEC) (Frankfurt:3CM) (OTC:CANVF) for an Investor Presentation. 

Source: www.newswire.ca

Great North will be exclusive representative for Aurora’s leading portfolio of Canadian brands

NYSE | TSX: ACB

Keep reading... Show less

The Company will now have meaningful operations in all 7 cannabis markets that fall within the top 10 most populated states in the U.S.

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or “the Company”), one of the largest vertically integrated, multistate cannabis operators in the United States, and Bluma Wellness Inc. (CSE: BWEL.U) (OTCQX:BMWLF) (“Bluma”), a vertically integrated operator in Florida, announced today they have entered into a definitive agreement (the “Agreement”) pursuant to which Cresco Labs will acquire all of the issued and outstanding shares of Bluma (“Bluma Shares”) in an all-share transaction that values Bluma at an equity value of US$213 million (the “Transaction”).

Keep reading... Show less

Reports Net Revenue of $160.5 Million , an Increase of 33% from Prior Year Quarter
Adjusted EBITDA of $12.6 Million Marks Seventh Consecutive Quarter of Increasing Positive Adjusted EBITDA
Cash Cost Per Gram Decreases for the Fifth Consecutive Quarter to $0.79
Completed Accretive, Strategic Acquisition of SweetWater

 Aphria Inc. (” Aphria ,” ” we ,” or the ” Company “) (TSX: APHA) (Nasdaq: APHA), a leading global cannabis-lifestyle consumer packaged goods company inspiring and empowering the worldwide community to live their very best life, today reported its financial results for the second quarter and six months ended November 30, 2020 . All amounts are expressed in Canadian dollars, unless otherwise noted and except for per gram, kilogram, kilogram equivalents, and per share amounts.

Keep reading... Show less

ACQUISITION OF OPTION TO MAINTAIN PRO RATA OWNERSHIP INTEREST OF APPROXIMATELY 20% FOLLOWING TERRASCEND FINANCING

 Canopy Growth Corporation (” Canopy Growth ” or the ” Company “) (TSX: WEED) (NASDAQ: CGC) today announced that the Company has filed an early warning report under National Instrument 62-103 in connection with the acquisition of an option (the ” Option “) to purchase 1,072,450 common shares (the ” Common Shares “) of TerrAscend Corp. (” TerrAscend “), conditional upon the occurrence or waiver of amendments to federal laws of the United States to permit the general cultivation, distribution and possession of marijuana (as defined in 21 U.S.C 802) or to remove the regulation of such activities from the federal laws of the United States (the ” Triggering Event “). Upon the occurrence or waiver of the Triggering Event, the Company may exercise the Option and pay the balance of the purchase price in order to acquire the Common Shares subject to the Option.

Keep reading... Show less

HempFusion Wellness Inc. (TSX:CBD.U) (“ HempFusion ” or the “ Company ”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce its entrance into the European market through an exclusive distribution agreement with a European distributor with an extensive retail store network. With full acknowledgement of the Food Safety Authority of Ireland (FSAI), the expansion includes fully European Union compliant labeling, packaging and distribution for select HempFusion CBD & Probulin Probiotics products.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210114005361/en/

Keep reading... Show less